Abcam plc, a global leader in the supply of life science research tools, is pleased to announce the appointment of Giles Kerr as a non-executive Director with effect from 12 December 2018.
Giles has extensive experience as an executive and non-executive Director in a wide range of public and private organisations. He recently stepped down as Finance Director of Oxford University, a position he had held since 2005. He remains a non-executive Director of Arix Biosciences plc, Adaptimmune Therapeutics plc, Senior plc, PayPoint plc as well as Oxford Sciences Innovation. From 1990 to 2004 Giles held a number of roles at Amersham plc, including Group Finance Director. Giles is a graduate in Economics from the University of York and a Chartered Accountant.
Peter Allen, Chairman of Abcam said: "I am delighted Giles is joining the Board of Abcam. Giles brings a wealth of experience within the life science sector, finance and a first-hand understanding of our academic research customers. He will make a valuable contribution to our Board."
Giles Kerr commented: "I have known and admired Abcam’s business for many years and am proud to be able to join the team. I look forward to working with the Board as the Company continues to execute on its strategy and build on its position as global leader."
Giles will join the Audit & Risk Committee.
The composition of each of the Board Committees has also been amended and is confirmed as follows:
Board Committee
Membership
Nomination Committee
Peter Allen (Chairman)
Louise Patten
Sue Harris
Mara Aspinall
Remuneration Committee
Louise Patten (Chairman)
Peter Allen
Sue Harris
Mara Aspinall
Audit and Risk Committee
Sue Harris (Chairman)
Peter Allen
Louise Patten
Giles Kerr